文献速递慢性静脉疾病

射频消融术后降低严重内膜热诱导血栓形成率的策略

Strategies to reduce rates of severe endothermal heat-induced thrombosis following radiofrequency ablation.
PubMed 文献 · J Vasc Surg Venous Lymphat Disord · 2024-03-20

该回顾性队列对照研究利用血管质量倡议数据库,评估单中心2018年实施的两项策略(大隐静脉直径≥8 mm或隐股交界直径≥10 mm者围术期单次预防剂量低分子肝素、每次手术仅治疗一条静脉)对射频消融术后血栓并发症的影响。结果显示总体内膜热诱导血栓形成率从2.6%降至1.5%(P=0.096),严重内膜热诱导血栓形成(≥III级)率显著降低(2.34 vs 0.366,P=0.020),限制治疗一条静脉与严重内膜热诱导血栓形成减少相关,而围术期低分子肝素无显著关联。

要点

  • 政策实施后总体内膜热诱导血栓形成率从2.6%降至1.5%,差异趋势接近显著(P=0.096)。
  • 严重内膜热诱导血栓形成(≥III级)率从2.34降至0.366(P=0.020)。
  • 治疗两条及以上静脉和静脉直径增大与内膜热诱导血栓形成风险增加相关(P=0.049和P<0.001)。

核心结论

  • 机构政策改变降低了内膜热诱导血栓形成率,在大隐静脉直径≥8 mm或隐股交界直径≥10 mm并接受射频消融的患者中严重内膜热诱导血栓形成率降低。
  • 所实施的改变中,限制每次手术仅治疗一条静脉与严重内膜热诱导血栓形成减少相关。
  • 围术期低分子肝素未显示关联,但可能发生2型错误。
  • 作者认为应探索预防血栓并发症的替代策略,如增加围术期抗凝的剂量和持续时间、使用抗血小板药物以及非药物策略。

研究设计与样本

  • 回顾性队列对照研究,使用血管质量倡议数据库。
  • 纳入2015年1月至2022年7月接受射频消融且大隐静脉直径≥8 mm或隐股交界直径≥10 mm的患者。
  • 符合纳入标准者共845例,其中政策改变前298例,政策改变后547例。

主要发现

  • 政策改变后,总体静脉中心内膜热诱导血栓形成率从2.6%降至1.5%,趋势接近显著(P=0.096)。
  • 政策改变后,分类为≥III级的内膜热诱导血栓形成率显著降低(2.34 vs 0.366;P=0.020)。
  • 治疗两条及以上静脉与内膜热诱导血栓形成风险增加相关(P=0.049)。
  • 静脉直径增大与内膜热诱导血栓形成风险增加相关(P<0.001)。
  • 围术期抗凝与全因血栓并发症或内膜热诱导血栓形成无显著关联(分别为P=0.563和P=0.885)。

临床怎么用

  • 对于大隐静脉直径≥8 mm或隐股交界直径≥10 mm接受射频消融的患者,本研究中心的做法是围术期给予单次预防剂量低分子肝素并限制每次手术仅治疗一条静脉。
  • 本研究中心的做法中,限制治疗一条静脉与严重内膜热诱导血栓形成减少相关。
  • 作者建议探索增加围术期抗凝剂量和持续时间、抗血小板使用及非药物策略等替代措施。

局限性

  • 原文提到围术期低分子肝素未显示关联,但可能发生2型错误。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Endothermal heat-induced thrombosis (EHIT) is a potential complication of radiofrequency ablation (RFA). Data on effective prophylaxis of EHIT are limited. In 2018, a high-volume, single institution implemented strategies to decrease the incidence of EHIT, including a single periprocedural prophylactic dose of low-molecular-weight heparin to patients with a great saphenous vein (GSV) diameter of ≥8 mm or saphenofemoral junction (SFJ) diameter of ≥10 mm and limiting treatment to one vein per procedure. The size threshold was derived from existing literature. The study objective was to evaluate the effects of these institutional changes on thrombotic complication rates after RFA. METHODS: A retrospective cohort control study was conducted using the Vascular Quality Initiative database. Data were collected for patients who underwent RFA with a GSV diameter of ≥8 mm or SFJ diameter of ≥10 mm from January 2015 to July 2022. The clinical end points were thrombotic complications (ie, thrombophlebitis, EHIT, deep vein thrombosis) and bleeding complications. Patient demographic and procedural variables were included in the analysis, and significant variables after univariable logistic regression were included in a multivariable logistic regression. RESULTS: After the policy change, the overall vein center EHIT rate decreased from 2.6% to 1.5%, with a trend toward significance (P = .096). The inclusion criterion of a GSV diameter of ≥8 mm or an SFJ diameter of ≥10 mm yielded 845 patients, of whom 298 were treated before the policy change and 547 after. There was a significant reduction in the rate of EHIT classified as class ≥III (2.34 vs 0.366; P = .020) after the institutional changes. Treatment of two or more veins and an increased vein diameter were associated with an increased risk of EHIT (P = .049 and P < .001, respectively). No significant association was found between periprocedural anticoagulation and all-cause thrombotic complications or EHIT (P = .563 and P = .885, respectively). CONCLUSIONS: The institutional policy changes have led to lower rates of EHIT, with a reduction in severe EHIT rates in patients with an ≥8-mm diameter GSV or a ≥10-mm diameter SFJ treated with RFA. Of the changes implemented, restricting treatment to one vein was associated with a reduction in severe EHIT. No association was found with periprocedural low-molecular-weight heparin, although a type 2 error might have occurred. Alternative strategies to prevent thrombotic complications should be explored, such as increasing the dosage and duration of periprocedural anticoagulation, antiplatelet use, and nonpharmacologic strategies.

来源:J Vasc Surg Venous Lymphat Disord,查看原文。版权归原作者所有。

引用

  1. Kedwai BJ, Geiger JT, Lehane DJ, et al. Strategies to reduce rates of severe endothermal heat-induced thrombosis following radiofrequency ablation. J Vasc Surg Venous Lymphat Disord. 2024. PMID: 38518986. doi:10.1016/j.jvsv.2024.101864

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。